Eiger Biopharmaceuticals (EIGR) Given Media Impact Score of 0.27

Media coverage about Eiger Biopharmaceuticals (NASDAQ:EIGR) has been trending positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.0456916259849 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Eiger Biopharmaceuticals (EIGR) traded up $0.05 during midday trading on Friday, hitting $8.65. The company had a trading volume of 52,529 shares, compared to its average volume of 246,442. The company has a market cap of $92.02, a P/E ratio of -1.63 and a beta of 1.91. Eiger Biopharmaceuticals has a 1-year low of $6.10 and a 1-year high of $16.20. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19.

A number of research firms have commented on EIGR. Oppenheimer set a $34.00 target price on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Tuesday, January 9th. ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 price target (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services initiated coverage on Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 price target on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Eiger Biopharmaceuticals has an average rating of “Buy” and a consensus price target of $27.25.

ILLEGAL ACTIVITY WARNING: “Eiger Biopharmaceuticals (EIGR) Given Media Impact Score of 0.27” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/17/eiger-biopharmaceuticals-eigr-given-media-impact-score-of-0-27.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply